Low-Dose Digoxin in Heart Failure: What the DECISION Trial Reveals About Safety and Efficacy
May 11, 2026
For decades, digoxin has been a cornerstone in the management of heart failure, particularly in patients with reduced or mildly reduced ejection fraction (HFrEF and HFmrEF). However, its role in contemporary heart failure therapy—where treatments like beta-blockers, ACE inhibitors and SGLT2 inhibitors dominate—has been questioned. The recent DECISION trial, the largest randomized, placebo-controlled study of low-dose digoxin in modern heart failure populations, offers critical insights. Here’s what clinicians and patients need to know.
Key Findings: Digoxin’s Place in Modern Heart Failure Care
The Bottom Line
- No significant benefit in reducing the composite of worsening heart failure events and cardiovascular death when added to guideline-directed therapy.
- Safe profile confirmed, with no increase in adverse effects or pacemaker implantations.
- Elderly patients (mean age 72) tolerated digoxin well, addressing past concerns about higher discontinuation rates.
- Similar efficacy in women, contrary to earlier post-hoc analyses suggesting harm in higher digoxin levels.
The DECISION trial enrolled over 1,000 patients with heart failure and LVEF ≤40% (or HFmrEF with LVEF 41–49%), randomized to low-dose digoxin (target serum concentration: 0.5–0.9 ng/mL) or placebo, on top of contemporary background therapy. The primary outcome—a composite of worsening heart failure events and cardiovascular death—occurred in 32% of digoxin patients versus 34% of placebo, a non-significant difference (RR 0.76, 95% CI 0.56–1.03).
Why didn’t digoxin show a benefit? Several factors likely contributed:
- High discontinuation rates (30% in the digoxin arm), reducing statistical power. The COVID-19 pandemic disrupted trial conduct, with hospital visits replaced by telemedicine.
- Advanced background therapy: More placebo patients received SGLT2 inhibitors during the trial, potentially masking digoxin’s effects.
- Older, sicker population: The mean age of 72 reflects real-world heart failure demographics but may have led to higher dropout rates.
Safety: Digoxin Remains a Low-Risk Option
Contrary to earlier concerns—particularly from post-hoc analyses of the DIG trial suggesting harm in women—the DECISION trial found no increased risk of adverse effects in the 284 women enrolled. This aligns with findings from the DIGIT-HF trial, which also showed safety in women with low-dose digitoxin.
Key Safety Data:
- No increase in arrhythmias or pacemaker implants.
- Serum digoxin concentrations were tightly controlled, with <90% of patients in the target range (0.5–0.9 ng/mL).
- Discontinuations were not primarily due to side effects but rather logistical challenges (e.g., pandemic-related barriers).
This trial reassures clinicians about digoxin’s safety in contemporary practice, particularly for patients who cannot tolerate other rate-control agents like beta-blockers or amiodarone.
Clinical Implications: Should You Prescribe Digoxin?
The DECISION trial adds to a growing body of evidence on digoxin’s role in heart failure. Here’s how to interpret the data:
| Trial | Population | Primary Outcome | Effect on Worsening HF | Safety Signal |
|---|---|---|---|---|
| DIG (1997) | HFrEF (LVEF ≤45%) | All-cause mortality | No effect on mortality; 28% RR reduction in HF hospitalizations | Neutral (but higher SDC in women linked to harm) |
| DIGIT-HF (2019) | HFrEF (LVEF ≤40%) + AF | First HF hospitalization or death | 15% RR reduction | Safe (low-dose digitoxin) |
| DECISION (2026) | HFrEF/HFmrEF (LVEF ≤49%) | Worsening HF + CV death | Non-significant trend (RR 0.76) | Safe (no increase in adverse events) |
When might digoxin still be considered?
- Rate control in atrial fibrillation: DECISION confirms digoxin’s safety in AF patients, complementing the RATE-AF trial, which showed similar efficacy to beta-blockers for quality of life but better HF outcomes.
- Cost-effective alternative: Digoxin is inexpensive and widely available, making it a viable option in resource-limited settings.
- Symptomatic relief: Some patients experience improved dyspnea or fatigue, even if hard outcomes aren’t affected.
Caveats
- Digoxin should not replace guideline-directed therapies (e.g., SGLT2 inhibitors, beta-blockers).
- Monitor serum concentrations closely to avoid toxicity, especially in elderly patients or those with renal impairment.
- Avoid in patients with severe HFpEF (LVEF >50%), where evidence is lacking.
FAQ: Digoxin in Heart Failure
1. Does digoxin improve survival in heart failure?
No. The DECISION trial and prior studies (DIG, DIGIT-HF) show digoxin does not reduce all-cause or cardiovascular mortality. Its benefit lies in reducing hospitalizations for worsening heart failure, particularly in patients with LVEF ≤40%.
2. Is digoxin safe in women?
Yes. Earlier concerns from the DIG trial (which used higher doses) were linked to supratherapeutic levels (>1.2 ng/mL). DECISION and DIGIT-HF confirm that low-dose digoxin (0.5–0.9 ng/mL) is safe in women, with no increased risk of adverse effects.
3. Can digoxin be used alongside SGLT2 inhibitors?
Yes. DECISION found no interactions between digoxin and SGLT2 inhibitors. However, both therapies should be used according to guidelines, with close monitoring for volume status changes.
4. What’s the target digoxin level for heart failure?
0.5–0.9 ng/mL. Higher levels (>1.2 ng/mL) increase toxicity risk without additional benefit. The DECISION trial’s dosing algorithm successfully maintained most patients in this range.
The Future of Digoxin in Heart Failure
The DECISION trial provides reassuring safety data for low-dose digoxin in contemporary heart failure therapy but does not support its routine use as a primary therapy. Digoxin remains a secondary option for:
- Rate control in AF, especially in patients intolerant to beta-blockers.
- Symptom management in HFrEF/HFmrEF when other therapies are maximized.
- Low-resource settings where newer agents are unavailable.
As heart failure guidelines evolve—particularly with the growing role of SGLT2 inhibitors and ARNI—digoxin’s place may shrink further. However, for now, it remains a safe, low-cost tool in the cardiologist’s arsenal.
Bottom Line: Digoxin is not a “game-changer” for heart failure outcomes, but it’s not obsolete either. Use it judiciously, at low doses, and with careful monitoring.